Selank

A synthetic heptapeptide analog of the body's own tuftsin, studied in research on anxiety regulation and cognitive function.

Selank is a heptapeptide derived from the body's own tetrapeptide tuftsin, originally developed in Russia as an anxiolytic. Research links it to anxiety-regulating and mildly cognition-supporting effects, without the sedation typical of benzodiazepines.

Facts

• CAS number: 129954-34-3
• Molecular weight: 751.9 g/mol
• Amino acids: 7
• Purity specification: ≥ 98 % (HPLC, commercial standard)

Evidence

• A randomized trial in 62 people with generalized anxiety disorder or neurasthenia compared the anxiolytic effect of selank to medazepam, with additionally observed improvements in energy and concentration without sedation. Zozulya AA et al. 2008, Bjulleten Eksperimentalnoj Biologii i Mediciny, PMID 18454096
• In an fMRI study with 52 healthy participants, selank administration was associated with altered functional connectivity between the right amygdala and right temporal cortex, measurable as early as 5 minutes after application. Panikratova KR et al. 2020, Doklady Biological Sciences, Bd. 490, S. 9-11

Frequently asked questions

Is selank the same as a benzodiazepine?
No. Both act on the GABA system in different ways. Selank binds at a different site and showed no sedative or dependence potential in studies, unlike classic benzodiazepines.

Where does selank come from?
Selank was developed at the Russian Academy of Sciences from the body's own peptide tuftsin, with a stabilizing addition for a longer duration in the body.

Is selank legally available in Germany?
Selank is not approved as a medication in Germany or the EU. It is offered exclusively as a research chemical for laboratory purposes, not for human use.

Documented prices

List prices excluding shipping and discounts. Currency and product variants must be compared separately. Availability and delivered batch have not been verified.